Results 221 to 230 of about 169,102 (267)

Determining the Usefulness of Selected Laboratory Markers of Inflammation in Qualifying Patients for T2 Biosystems Determination

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Improving treatment outcomes sepsis requires early recognition, the implementation of appropriate treatment, and targeted antimicrobial therapy. One method for rapid diagnosis is the amplified magnetic resonance imaging—T2 Biosystems, USA (T2Dx). Proper patient qualification for T2Dx testing can significantly contribute to reducing the time to initiate
Mateusz Szymański   +2 more
wiley   +1 more source

Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract To evaluate the pharmacodynamic effects and clinical outcomes of orally administered once‐daily govorestat (AT‐007), a central nervous system penetrant aldose reductase inhibitor, the double‐blind placebo‐controlled ACTION‐Galactosemia Kids study (NCT04902781) randomly assigned 47 participants (2–17 years old) with Classic Galactosemia to 18 ...
Evan Bailey   +17 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Pediatric asthma exacerbations represent a significant cause of emergency department use and hospitalizations. Despite available treatment options, many children's exacerbations are refractory to standard therapies and require adjunct treatments.
Joseph E. Rower   +6 more
wiley   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Home - About - Disclaimer - Privacy